Vun-Sin Lim, PhD

1.2K posts

Vun-Sin Lim, PhD

@vs_lim

Managing Editor of the Journal of Thoracic Oncology | Tweets are my own | Bluesky handle: https://t.co/K8lNk59Kq3

Asia Pacific Katılım Ekim 2013

355 Takip Edilen357 Takipçiler

Sabitlenmiş Tweet

Vun-Sin Lim, PhD@vs_lim·18 Eyl

#WCLC25 It takes a village! Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @IASLC! @DrAlexAdjei @JTOonline @ElsevierConnect #JTO #JTOCRR

English

706

Vun-Sin Lim, PhD@vs_lim·21h

@JTOonline @IASLC

Laura Alder, MD@LauraAlderMD

New in @JThoracOncol: 📌 Compound (PACC/PACC AND PACC/classical) mutations both show enhanced sensitivity to 2nd-gen TKIs (afatinib) over osimertinib in 1L 📌 PACC pts on 1L osimertinib trended toward shorter ToT vs classical (19.5 vs 28.5 mo) 🧬 Bottom line: When you see a compound mutation with a PACC component (G719X, S768I, E709X) — even if paired with L858R or Ex19del — treat it as PACC. Consider 2nd-gen TKIs over osimertinib. ⭐️Still an area of unmet need! Novel agents like firmonertinib, silevertinib enozertinib are being studied. Great effort by @LeXiuning and team! jto.org/article/S1556-…

QAM

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·1d

We’re grateful to Jacek Jassem for 7 years of helping shape JTO and advance research! #JTO20

English

276

Vun-Sin Lim, PhD retweetledi

d.planchard@dplanchard·3d

Thrilled to discuss the critical role of HER2 testing in NSCLC & the impressive monotherapy activity of ADCs (like T-DXd) from our Phase 1b DESTINY-Lung03 trial! @JTOonline Grateful to an amazing team of co-authors! Clink the link to read 👇 @IASLC #Lungcancer #HER2

JTO & JTO CRR@JTOonline

According to DESTINY-Lung03, T-DXd showed durable antitumor activity and a manageable safety profile in previously treated HER2 IHC 3+/2+ #NSCLC, supporting routine #HER2 IHC testing in diagnostic workup. Read more: bit.ly/4dai726

English

2.1K

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·3d

English

2.7K

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·4d

We honor Johan Vansteenkiste for 9 years of dedication to thoracic oncology and JTO. #JTO20

English

256

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·5d

Thoracic imaging is redefining #lungcancer care. Advances in CT, PET, MRI, radiomics, radiogenomics, and AI are helping clinicians detect disease earlier, personalize therapy, and better assess response to treatment. Read more: bit.ly/4tR7CWC #JTO20

English

429

Vun-Sin Lim, PhD retweetledi

Stephen V Liu, MD@StephenVLiu·6d

China subgroup analysis from ADRIATIC (consolidation durvalumab post chemoradiation for LS-SCLC vs placebo) @JTOonline. China PFS HR 0.67 with mPFS 22.9m vs 14.3m (overall study PFS 16.6 vs 9.2m) and OS HR 0.71 (3y rate 64% vs 55% - overall 57% vs 48%). jtocrr.org/article/S2666-…

English

1.5K

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·6d

Congrats🎉to Dr. Michele Carbone on being awarded the 2026 Szent-Györgyi Prize for Progress in #Cancer Research from @NFCR. Dr. Carbone serves as an Associate Editor of the Journal and was recently recognized as one of our top reviewers.👏 Read more: bit.ly/43maKie

English

Vun-Sin Lim, PhD@vs_lim·6d

@OncodailyLung @dplanchard Thank you! Also tagging @DrAlexAdjei @TommyJohn00 @DrBonnieKy

English

OncoDaily Lung@OncodailyLung·6d

JTO Insights Podcast Episode 3 Highlights Key Takeaways from JTO May Issue - Vun-Sin Lim @vs_lim @dplanchard oncodaily.com/voices/vun-sin…

English

1.3K

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·6d

ZXX

404

Vun-Sin Lim, PhD retweetledi

Lei Deng, MD (He/Him)@LeiDeng3·19 May

Calling on all @HemOncFellows with interest in lung cancer. If you're going to ASCO, @HwakeleeMD @RamalingamMD and I will have a dedicated event for you on 5/30 Saturday evening. Scan to register. @donnashort @precisca_

English

1.5K

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·19 May

#LungCancer care in #Morocco faces major gaps in diagnostics, molecular testing, treatment access, and survivorship support. This review highlights barriers across the care continuum and policy reforms that could improve equitable #ThoracicOncology care: bit.ly/4nz7pG8

English

275

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·19 May

Behind every milestone is sustained dedication. Celebrating Ramon Rami-Porta and 7 years of impact. #JTO20

English

326

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·16 May

Nine years of service, lasting impact. Celebrating Tetsuya Mitsudomi as part of #JTO20

English

518

Vun-Sin Lim, PhD@vs_lim·15 May

@herbloong @dplanchard @GustaveRoussy @CUHKMedicine @mollylisc He was just on our JTO podcast, released on Thursday!!

English

265

Herbert Loong, MBBS, FASCO@herbloong·15 May

Always a pleasure to welcome @dplanchard of @GustaveRoussy 🇫🇷 to #hongkong 🇭🇰! Thanks for sharing with us your insights in contemporary management of #HER2positive #NSCLC. Had excellent discussions with local #thoraciconcology experts in the field. @CUHKMedicine @mollylisc #LCSM @apoddc @APCLC_2023 #precisiononcology @IASLC

English

1.3K

Vun-Sin Lim, PhD retweetledi

JTO & JTO CRR@JTOonline·15 May

New JTO Insights episode 🎧 Drs. Alex Adjei and @TommyJohn00 discuss cardiac dysfunction after RT for #lungcancer and DESTINY-Lung03 findings in HER2-overexpressing #NSCLC with Drs. @DrBonnieKy and David Planchard. Listen now: bit.ly/48XeXfM

English

579

Vun-Sin Lim, PhD retweetledi

IASLC@IASLC·15 May

We’re hiring! 📢 Open roles: 🔹 Philanthropy Manager 🔹 AMS & Data Performance Manager Join our global team advancing #lungcancer research, education, & care worldwide. Learn more & apply today: bit.ly/4wKdSSK #Hiring #Jobs #Denverjobs